Literature DB >> 17343610

Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.

K Domanska1, S Malander, A Måsbäck, M Nilbert.   

Abstract

At least one of ten patients with ovarian cancer is estimated to develop their tumor because of heredity with the breast and ovarian cancer syndrome due to mutations in the BRCA1 and BRCA2 genes and hereditary nonpolyposis colorectal cancer (HNPCC) being the major genetic causes. Cancer at young age is a hallmark of heredity, and ovarian cancers associated with HNPCC have been demonstrated to develop at a particularly early age. We used the Swedish Cancer Registry to identify a population-based series of 98 invasive epithelial ovarian cancers that developed before 40 years. Mucinous and endometrioid cancers were overrepresented and were diagnosed in 27% and 16% of the tumors, respectively. Immunostaining using antibodies against MLH1, PMS2, MSH2, and MSH6 was used to assess the mismatch-repair status and revealed loss of expression of MLH1/PMS2 in two cases, loss of MSH2/MSH6 in one case, and loss of MSH6 only in three tumors. A microsatellite instability-high phenotype was verified in five of six tumors. Based on the identified mutations and family history of cancer, several of these individuals are likely to be affected by HNPCC. We conclude that although the causes of the vast majority of epithelial ovarian cancer at young age are unknown, HNPCC should be considered because of the high risk of metachronous colorectal cancer in the individual and the possibility of preventing additional cancers in the family through control programs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343610     DOI: 10.1111/j.1525-1438.2007.00875.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  15 in total

Review 1.  The inherited genetics of ovarian and endometrial cancer.

Authors:  Simon A Gayther; Paul D P Pharoah
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

Review 2.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

3.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

4.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.

Authors:  Koah R Vierkoetter; Asia R Ayabe; Maya VanDrunen; Hyeong Jun Ahn; David M Shimizu; Keith Y Terada
Journal:  Gynecol Oncol       Date:  2014-08-02       Impact factor: 5.482

Review 5.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

7.  Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.

Authors:  Sue V Petzel; Rachel Isaksson Vogel; Tracy Bensend; Anna Leininger; Peter A Argenta; Melissa A Geller
Journal:  J Genet Couns       Date:  2013-05-16       Impact factor: 2.537

8.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

Authors:  Honglin Song; Susan J Ramus; Jonathan Tyrer; Kelly L Bolton; Aleksandra Gentry-Maharaj; Eva Wozniak; Hoda Anton-Culver; Jenny Chang-Claude; Daniel W Cramer; Richard DiCioccio; Thilo Dörk; Ellen L Goode; Marc T Goodman; Joellen M Schildkraut; Thomas Sellers; Laura Baglietto; Matthias W Beckmann; Jonathan Beesley; Jan Blaakaer; Michael E Carney; Stephen Chanock; Zhihua Chen; Julie M Cunningham; Ed Dicks; Jennifer A Doherty; Matthias Dürst; Arif B Ekici; David Fenstermacher; Brooke L Fridley; Graham Giles; Martin E Gore; Immaculata De Vivo; Peter Hillemanns; Claus Hogdall; Estrid Hogdall; Edwin S Iversen; Ian J Jacobs; Anna Jakubowska; Dong Li; Jolanta Lissowska; Jan Lubiński; Galina Lurie; Valerie McGuire; John McLaughlin; Krzysztof Medrek; Patricia G Moorman; Kirsten Moysich; Steven Narod; Catherine Phelan; Carole Pye; Harvey Risch; Ingo B Runnebaum; Gianluca Severi; Melissa Southey; Daniel O Stram; Falk C Thiel; Kathryn L Terry; Ya-Yu Tsai; Shelley S Tworoger; David J Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Penelope M Webb; Lynne R Wilkens; Anna H Wu; Hannah Yang; Wendy Brewster; Argyrios Ziogas; Richard Houlston; Ian Tomlinson; Alice S Whittemore; Mary Anne Rossing; Bruce A J Ponder; Celeste Leigh Pearce; Roberta B Ness; Usha Menon; Susanne Krüger Kjaer; Jacek Gronwald; Montserrat Garcia-Closas; Peter A Fasching; Douglas F Easton; Georgia Chenevix-Trench; Andrew Berchuck; Paul D P Pharoah; Simon A Gayther
Journal:  Nat Genet       Date:  2009-08-02       Impact factor: 38.330

Review 9.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

10.  Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Authors:  Jenny Permuth-Wey; David Boulware; Nikola Valkov; Sandra Livingston; Santo Nicosia; Ji-Hyun Lee; Rebecca Sutphen; Joellen Schildkraut; Steven Narod; Alex Parker; Domenico Coppola; Thomas Sellers; Tuya Pal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.